Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 12, 2018
Reporting Period: Fourth quarter and full year ended December 31, 2017.
This filing serves as a notification that the Company issued a press release regarding its financial results for the specified period. The detailed financial data is contained in the press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not explicitly stated within the body of this 8-K filing.
Material Changes
The filing does not list specific material changes or comparative financial data versus prior periods. It solely announces the release of the Q4 and full-year 2017 results.
Guidance, Outlook, and Risks
- Conference Call: Management scheduled a conference call for February 28, 2018, at 9:00 a.m. Eastern Time to present the financial results. A live webcast was available on the Company's website.
- Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements (plans, strategies, intentions) which are subject to risks and uncertainties.
- Risk Factors: Investors are directed to Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, for a detailed discussion of risks.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2017 revenue, net loss, and cash position figures.
- Verify the details of the conference call held on February 28, 2018, for management commentary on the results.
- Consult the 2016 Form 10-K and Q2 2017 Form 10-Q for the comprehensive list of risk factors referenced in this filing.
- Confirm the Company's status as an emerging growth company and any related accounting election disclosures.